*Results may vary due to a variety of factors
Innovative Treatment for Stroke & Traumatic Brain Injury
Peri-Spinal Etanercept transforms lives from dysfunctional to functional. To see what is possible review the many videos shown below. Click on links to see the amazing recoveries that occur minutes after the injection even in patients with little to no function 10-20 years after their stroke or brain injury:
Most patients and physicians believe that after a stroke or traumatic brain injury, patients will NOT recover any new brain or neurological function after 2 years from the date of their original injury. While it is true most patients DO NOT develop any new brain or neurological function after two years, there are innovative therapies for Stroke, Traumatic Brain Injury [TBI], Alzheimers Dementia and Intractable Spine Pain that are restoring function and have transformed the treatment of these patient’s injuries. Peri-Spinal Etanercept is changing lives from hopeless to hopeful! Now patient’s who are even 10-20 years past their injury are recovering a tremendous amount of brain, neurological and or nervous system function. Peri-Spinal Etanercept was developed by Dr. Ed Tobinick who has transformed treatment of brain injury and strike worldwide. In spite of great controversy, through Dr. Tobinick’s pioneering efforts a federal judge in Florida and one in California declared that Peri-Spinal Etanercept is within the standard of care.
Results vary from spectacular or miraculous to no response or benefit. When patients respond to these treatments, they respond within minutes and or over 24-48 hours. Function, memory, vision, strength, mood and balance frequently improve very quickly. These treatments are offered by very few physicians across the country. Dr. Rafael Cruz was fortunate enough to train with the inventor of these patented treatments. Dr. Cruz is now offering all of these therapies at Kentuckiana Integrative Medicine.
for a consultation.
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment for these indications is innovative (“off-label” and not FDA approved).